| Aug 8 |
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 8 |
Nektar Therapeutics Non-GAAP EPS of -$0.19, revenue of $23.49M
|
| Aug 8 |
Nektar: Q2 Earnings Snapshot
|
| Aug 8 |
Nektar Therapeutics Reports Second Quarter 2024 Financial Results
|
| Aug 1 |
Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets
|
| Jul 16 |
Nektar Therapeutics' (NASDAQ:NKTR) large institutional owners must be happy as stock continues to impress, up 13% over the past week
|
| Jun 21 |
Nektar Therapeutics Likely To Drift And Wobble Ahead Of Key Phase II Data In 2025
|
| Jun 12 |
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
|
| Jun 5 |
Nektar Therapeutics' (NASDAQ:NKTR) investors will be pleased with their stellar 130% return over the last year
|
| May 30 |
Nektar Management to Present at Upcoming Investor Conferences
|
